Barclays PLC Increases Stock Holdings in ProAssurance Co. (NYSE:PRA)

Barclays PLC raised its stake in shares of ProAssurance Co. (NYSE:PRA) by 6.8% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 90,894 shares of the insurance provider’s stock after buying an additional 5,777 shares during the quarter. Barclays PLC owned about 0.18% of ProAssurance worth $1,447,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in PRA. Wealthfront Advisers LLC acquired a new position in ProAssurance during the fourth quarter worth approximately $359,000. Amundi boosted its stake in shares of ProAssurance by 182.3% during the 4th quarter. Amundi now owns 25,634 shares of the insurance provider’s stock valued at $389,000 after buying an additional 16,552 shares during the last quarter. Prudential Financial Inc. raised its stake in shares of ProAssurance by 57.3% in the 4th quarter. Prudential Financial Inc. now owns 86,703 shares of the insurance provider’s stock valued at $1,379,000 after purchasing an additional 31,580 shares in the last quarter. American Century Companies Inc. increased its holdings in shares of ProAssurance by 17.2% in the 4th quarter. American Century Companies Inc. now owns 391,609 shares of the insurance provider’s stock valued at $6,230,000 after acquiring an additional 57,556 shares during the last quarter. Finally, JPMorgan Chase & Co. lifted its position in shares of ProAssurance by 28.0% in the 4th quarter. JPMorgan Chase & Co. now owns 323,955 shares of the insurance provider’s stock worth $5,154,000 after buying an additional 70,780 shares during the last quarter. 85.58% of the stock is currently owned by hedge funds and other institutional investors.

ProAssurance Stock Down 0.1 %

PRA stock opened at $23.01 on Friday. The company has a current ratio of 0.28, a quick ratio of 0.28 and a debt-to-equity ratio of 0.35. The firm has a market cap of $1.18 billion, a PE ratio of 27.72 and a beta of -0.09. The company has a fifty day simple moving average of $20.74 and a 200 day simple moving average of $17.41. ProAssurance Co. has a 1 year low of $10.76 and a 1 year high of $23.70.

ProAssurance (NYSE:PRA) last released its earnings results on Monday, February 24th. The insurance provider reported $0.36 earnings per share for the quarter, topping analysts’ consensus estimates of $0.17 by $0.19. The firm had revenue of $287.52 million during the quarter, compared to analyst estimates of $274.56 million. ProAssurance had a net margin of 3.71% and a return on equity of 2.65%. Sell-side analysts anticipate that ProAssurance Co. will post 0.8 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of research firms have issued reports on PRA. StockNews.com initiated coverage on ProAssurance in a research note on Saturday. They issued a “hold” rating on the stock. Raymond James lowered shares of ProAssurance from a “market perform” rating to an “underperform” rating in a research report on Thursday, April 10th. Citigroup downgraded shares of ProAssurance to a “market perform” rating in a research report on Thursday, April 3rd. Finally, Citizens Jmp cut ProAssurance from an “outperform” rating to a “market perform” rating in a research note on Thursday, April 3rd. One investment analyst has rated the stock with a sell rating, five have issued a hold rating and one has issued a buy rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus target price of $18.67.

ProAssurance Profile

ProAssurance Corporation, through its subsidiaries, provides property and casualty insurance, and reinsurance products in the United States. The company operates through Specialty Property and Casualty, Workers’ Compensation Insurance, and Segregated Portfolio Cell Reinsurance segments. It offers professional liability insurance to healthcare providers and institutions, and attorneys and their firms; medical technology liability insurance to medical technology and life sciences companies; and custom alternative risk solutions, including assumed reinsurance, loss portfolio transfers, and captive cell programs for healthcare professional liability insureds.